Serum p53 Autoantibodies and Breast Cancer
Author Information
Author(s): B. Mudenda, J.A. Green, B. Green, J.R. Jenkins, L. Robertson, M. Tarunina, S.J. Leinster
Primary Institution: Royal Liverpool University Hospital
Hypothesis
The study aims to assess the clinical implications of serum antibodies to p53 by relating their incidence to tissue p53 protein expression and clinicopathological variables in breast cancer.
Conclusion
The presence of p53 autoantibodies is associated with poor histological grade and may provide additional information for identifying aggressive breast cancer types.
Supporting Evidence
- 26% of breast cancer patients had p53 autoantibodies compared to 1.3% of normal controls.
- Autoantibodies were found in all stages of breast cancer.
- Presence of p53 autoantibodies correlated with high histological grade.
- Lower incidence of autoantibodies was observed in patients with a family history of breast cancer.
- Positive p53 autoantibody status correlated with the detection of p53 protein in tissue sections.
Takeaway
This study found that many breast cancer patients have antibodies against a protein called p53, which might help doctors understand how aggressive the cancer is.
Methodology
Sera from 182 newly diagnosed breast cancer patients were tested for p53 autoantibodies using an ELISA method.
Limitations
The study may not account for all factors influencing p53 autoantibody presence, and the sample size may limit generalizability.
Participant Demographics
Patients were newly diagnosed breast cancer patients from the Royal Liverpool University Hospital.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website